These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1243 related items for PubMed ID: 21154129

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 3. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM, Bepler G.
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [Abstract] [Full Text] [Related]

  • 12. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 13. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R.
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [Abstract] [Full Text] [Related]

  • 14. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI, Gautschi O.
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [Abstract] [Full Text] [Related]

  • 15. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH, Mok K, Leung LK, Mok TS.
    Future Oncol; 2015 Sep; 11(5):735-45. PubMed ID: 25757678
    [Abstract] [Full Text] [Related]

  • 16. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 17. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 18. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT, Solomon B.
    Clin Cancer Res; 2011 Apr 15; 17(8):2081-6. PubMed ID: 21288922
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 15; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 20. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.